Code	DCL
Company name	Cuu Long Pharmaceutical Joint Stock Corporation
Date	02/12/2018
Subject	Report on the use of capital

## **Content:**

Cuu Long Pharmaceutical Joint Stock Corporation reports the use of capital from public offering as follows:

- I. <u>Stock in the public offering:</u>
- 1. Stock name: Stock of Cuu Long Pharmaceutical Joint Stock Corporation
- 2. Stock type: common share
- 3. Par value: VND10,000/share
- 4. Offering volume: 10,059,480 shares
- 5. Total mobilized capital: VND201,189,600,000.
- 6. Beginning date of public offering: July 28, 2015
- 7. Ending date of public offering: September 16, 2015
- II. <u>Plan for use of capital</u>

## 1. Progress of projects according to the Company's prospectus:

No.	Project	Amount
		(VND)
1	Invest in pharmaceutical factory	80,000,000,000
2	Invest in Capsule factory	65,000,000,000
3	Invest in Vikimco factory	50,000,000,000
4	Invest in means of transportation	11,000,000,000
5	Build depots	17,000,000,000
6	R&D	20,000,000,000
7	Expand branch system	1,000,000,000
8	Invest in the management software	20,000,000,000
9	Raise the working capital	50,000,000,000
	Total	314,000,000,000
	Of which:	
	- Proceeds from the stock issue	201,189,600,000

- Borrowing from banks	112,810,400,000
------------------------	-----------------

According to the document dated December 21, 2017, the Board of Directors adjusted the plan for capital use and this was adopted by the 2018 extraordinary general meeting dated January 05, 2018 as follows:

No.	Project	Amount (VND)
		$(\mathbf{V}\mathbf{N}\mathbf{D})$
1	Build workshop, purchase equipment,	97,052,300,000
	etc.	
2	Contribute capital to set up Benovas	54,137,300,000
	Cancer Drug Company	
3	Raise the working capital	50,000,000,000
	Total	201,189,600,000

## 2. Progress of projects at present:

The Company used VND147,052,300,000 of the proceeds according to the report of capital disbursement.

For the remaining capital, the Company used VND54,137,300,000 to contribute capital to establish Benovas Cancer Drug Company.

Therefore, until the present, the Company used all of the proceeds of the 2015 stock offering.